{"doi":"10.1111/acer.15062","title":"Self‐reported alcohol use versus phosphatidylethanol in behavioral trials: A study of people living with <scp>HIV</scp> in Tshwane, South Africa","abstract":"BACKGROUND: Accurately quantifying alcohol use among persons with HIV (PWH) is important for validly assessing the efficacy of alcohol reduction interventions. METHODS: We used data from a randomized controlled trial of an intervention to reduce alcohol use among PWH who were receiving antiretroviral therapy in Tshwane, South Africa. We calculated agreement between self-reported hazardous alcohol use measured by the Alcohol Use Disorders Identification Test (AUDIT; score ≥8) and AUDIT-Consumption (AUDIT-C; score ≥3 for females and ≥4 for males), heavy episodic drinking (HED) in the past 30 days, and heavy drinking in the past 7 days with a gold standard biomarker--phosphatidylethanol (PEth) level (≥50 ng/mL)--among 309 participants. We used multiple logistic regression to assess whether underreporting of hazardous drinking (AUDIT-C vs. PEth) differed by sex, study arm, and assessment time point. RESULTS: Participants' mean age was 40.6 years, 43% were males, and 48% were in the intervention arm. At 6 months, 51% had PEth ≥50 ng/mL, 38% and 76% had scores indicative of hazardous drinking on the AUDIT and AUDIT-C, respectively, 11% reported past 30-day HED, and 13% reported past 7-day heavy drinking. At 6 months, there was low agreement between AUDIT-C scores and past 7-day heavy drinking relative to PEth ≥50 (sensitivities of 83% and 20% and negative predictive values of 62% and 51%, respectively). Underreporting of hazardous drinking at 6 months was associated with sex (OR = 3.504. 95% CI: 1.080 to 11.364), with odds of underreporting being greater for females. CONCLUSIONS: Steps should be taken to decrease underreporting of alcohol use in clinical trials.","journal":"Alcohol Clinical and Experimental Research","year":2023,"id":367899,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.877,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":503605,"name":"Bronwyn Myers","orcid":"0000-0003-0235-6716","position":1,"is_corresponding":false},{"id":1060663,"name":"Mukhethwa Londani","orcid":"0000-0002-7054-237X","position":2,"is_corresponding":false},{"id":297724,"name":"Paul A. Shuper","orcid":"0000-0001-9033-8598","position":3,"is_corresponding":false},{"id":912504,"name":"Sebenzile Nkosi","orcid":"0000-0001-9901-1508","position":4,"is_corresponding":false},{"id":416059,"name":"Judith A. Hahn","orcid":"0000-0002-2697-8264","position":5,"is_corresponding":false},{"id":1061165,"name":"Connie T. Kekwaletswe","orcid":null,"position":6,"is_corresponding":false},{"id":1060665,"name":"Neo K. Morojele","orcid":"0000-0003-2891-2557","position":7,"is_corresponding":false},{"id":23213,"name":"Charles Parry","orcid":"0000-0001-9787-2785","position":0,"is_corresponding":true}],"reference_count":38,"raw_metadata":null,"created_at":"2026-07-19T01:15:16.306414Z","pmid":"36940726","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}